CLINICAL_TRIALS ClinicalTrials.gov record update

RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06814496
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:11.898120+00:00
Published At: 2025-10-09T00:00:00+00:00
Record Updated At: 2025-10-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Melanoma", "Medullary Thyroid Cancer", "Sinonasal Undifferentiated Carcinoma", "Esthesioneuroblastoma", "Bladder Cancer", "Testicular Cancer", "Glioblastoma Multiforme", "Cervical Cancer", "Large Cell Neuroendocrine Carcinoma of the Lung", "Non Small Cell Lung Cancer", "Merkel Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-09"
protocolSection.identificationModule.nctId: "NCT06814496"
protocolSection.identificationModule.officialTitle: "RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.